Targeted therapy for cancer in Istanbul, Turkey
Targeted therapy uses drugs — small-molecule inhibitors and monoclonal antibodies — that act on specific molecules a cancer depends on to grow and spread, blocking growth signals, cutting off its blood supply, or flagging it for the immune system. It only works when your tumour carries the matching target, so biomarker or molecular testing of the tumour comes first. Istanbul hospitals offer this pathway, often at JCI-accredited, state-authorized centers and well below Western-European prices for the same protocol. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
What targeted therapy is
The U.S. National Cancer Institute describes targeted therapy as a type of cancer treatment that uses drugs to target specific molecules — often called molecular targets— that are involved in the growth and spread of cancer cells. Because they act on the changes that set cancer cells apart, targeted drugs work differently from standard chemotherapy, which affects rapidly dividing cells more broadly. The NCI groups most targeted therapies into two kinds: small-molecule drugs, small enough to slip inside a cell (tyrosine kinase inhibitors are a common example), and monoclonal antibodies, larger proteins that attach to targets on the cell surface.
Per the NCI, these drugs can block the signals that tell cancer cells to grow, cut off the new blood vessels a tumour needs (angiogenesis inhibitors), carry a cell-killing agent directly to the cancer, or flag cancer cells so the immune system destroys them. The essential point is that targeted therapy is only useful when the tumour actually carries the target a drug is built to hit, which is why molecular testing comes first — and the NCI notes cancers can develop resistance to a targeted drug over time. Browse the wider cancer types hub for related diagnoses.
Treatment options
The ways the NCI describes targeted drugs working — and the testing that selects them — with an honest note on each:
- Small-molecule drugs. Small enough to enter a cell, these often block enzymes such as tyrosine kinases that relay growth signals inside the cancer. They are usually taken as pills over many cycles, so cost scales with how long you stay on the drug — and resistance can eventually force a switch.
- Monoclonal antibodies. Larger proteins that attach to a target on the cell surface — some block growth signals, some carry a cell-killing agent to the cancer, and some flag it for the immune system. They are given by infusion, and which antibody fits depends on your tumour’s markers.
- Angiogenesis inhibitors. A group of targeted drugs the NCI describes as cutting off the new blood vessels a tumour needs to keep growing. Whether one applies, and alongside which other therapy, depends on your cancer type and stage — not a template.
- Biomarker / molecular testing (the gate). The tumour — or blood, in a liquid biopsy — is tested to find an actionable target such as HER2, EGFR, ALK, BRAF, KRAS or BRCA. Without a matching target the drug will not help, so this testing decides whether targeted therapy is even an option for you.
See how these modalities work in general on the treatments & technology hub.
What it costs
There is no single targeted-therapy price, because the cost is driven by which drug is matched to your tumour, how many cycles you receive, and the molecular testingneeded to select the drug in the first place — the drugs are priced per cycle and usually dominate the total, and a switch of drug after resistance can change the picture again. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling oncologists or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose medical-oncology and molecular-pathology capability fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
This is one treatment modality within the broader cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your pathology, imaging and any molecular testing into a plain-language case file in your language before you decide whether to travel.
Related treatments & diagnostics
Check everything here — us included
Common questions
Can I get targeted therapy in Turkey?
Yes. Istanbul hospitals prescribe the targeted-therapy drugs the U.S. National Cancer Institute describes — small-molecule inhibitors and monoclonal antibodies that act on the specific molecules driving a cancer’s growth. The catch is that these drugs only work when your tumour carries the matching target, so biomarker or molecular testing of the tumour (or a blood-based liquid biopsy) has to come first. Many centers hold JCI accreditation and Turkish Ministry of Health state authorization, both of which you can check yourself before you commit. The honest first step is a free case review of your pathology, imaging and any molecular reports so it is clear whether a target has been found.
Why do I need biomarker or molecular testing first?
Because targeted therapy is target-matched, not one-size-fits-all. Per the NCI, these drugs are designed to act on a specific molecular target — a protein or gene change — that a cancer depends on to grow and spread. Testing the tumour tissue, or blood in a liquid biopsy, is how a lab finds whether that target is present. If your cancer does not carry the target a given drug hits, the drug will not help you, however advanced it is. This is why a modern workup includes molecular or genomic testing, and why a case review will flag whether that testing has already been done on your reports.
What molecular targets are commonly tested?
It depends on the cancer type, but the NCI notes that targeted therapy is guided by biomarkers found through tumour testing. Commonly tested targets include HER2 (in breast and stomach cancers), EGFR and ALK (in lung cancer), BRAF (in melanoma and others), KRAS, and BRCA gene changes that point to drugs called PARP inhibitors. A pathology or molecular report will name which markers were tested and whether any were positive. A case review reads those reports and tells you what has and has not yet been established, so you know whether a targeted option is even on the table. This is general information, not a treatment recommendation.
How much does targeted therapy cost in Istanbul?
There is no single figure, because the cost is driven by which drug is matched to your tumour, how many cycles you receive, and the molecular testing needed to select the drug in the first place — targeted drugs are priced per cycle and usually dominate the total, and resistance can mean a switch of drug over time. Istanbul typically runs well below Western-European prices for the same protocol, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real written quote line by line. See the Turkey Oncology Price Index for current ranges.
Start with a free 72-hour case review
Send your pathology and imaging. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.